BRIEF—Positive Phase III data for Viaskin Peanut

Positive results from the Phase III EPITOPE trial of Viaskin Peanut, a peanut allergy treatment under development by DBV Technologies, have been published in the New England Journal of Medicine.

After one year, those in the test group achieved a statistically superior level of desensitization compared with placebo, respectively 67% and 33.5%.

Viaskin is a novel form of EPIT and a potential new class of treatment that harnesses the immune properties of the skin.

Scientists at DBV believe the new approach will allow the treatment of peanut allergy in children by providing very low doses on the surface of the skin.

There are currently no approved treatment options for peanut-allergic children under the age of four.